Top Markets
#1 Helium Helium +57.25%
#2 Seeker Seeker +36.80%
#3 Pons Pons +26.62%
#4 TENDIES TENDIES +24.40%
#5 Zylo Ecosystem Zylo Ecosystem +24.40%
#6 UnifAI Network UnifAI Network +21.04%
#7 Bounce Bounce +20.57%
#8 Zora Zora +14.78%
#9 DAPPOS DAPPOS +13.42%
#10 ZKsync ZKsync +12.91%
Coin of the day
Helium Helium
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Clasificación en acciones #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Precio por acción
$9.50
Última sincronización: 2025-01-08
Capitalización bursátil
$819.52M
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Poseida Therapeutics, Inc. (PSTX)

Categoría

Healthcare
Margen Operativo de Poseida Therapeutics, Inc. (PSTX)
Margen Operativo al August 2026 TTM: -200.15%
Según los informes financieros más recientes y el precio de las acciones de Poseida Therapeutics, Inc., el margen operativo actual (TTM) es -200.15%. Al final de 2022, el margen operativo era -45.98%.
Historial de Margen Operativo de Poseida Therapeutics, Inc. desde 2016 hasta 2026
Margen Operativo al final de cada año
Año Margen Operativo Cambiar
2026 (TTM) -200.15% 0.00%
2023 -200.15% 335.30%
2022 -45.98% -89.84%
2021 -452.69% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% -100.00%
2017 -658.89% 1,081.23%
2016 -55.78% 0.00%
Margen Operativo de empresas similares o competidoras
Empresa Margen Operativo Diferencia de Margen Operativo País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -100.19%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -100.14%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -100.13%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -99.26%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.